Selected research
Market Outlook & Growth Opportunities
Global Pharmaceutical Rapid Sterility Testing Market Outlook and Growth Opportunities 2026
Market perspective
The global Pharmaceutical Rapid Sterility Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Pharmaceutical Rapid Sterility Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Pharmaceutical Rapid Sterility Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pharmaceutical Rapid Sterility Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Pharmaceutical Rapid Sterility Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Pharmaceutical Rapid Sterility Testing market include Steris PLC, Charles River Laboratories International, Inc., Thermo Fisher Scientific, Inc., SGS S.A., Sartorius AG, Sotera Health Company, Pacific Biolabs, Inc., Laboratory Corporation of America Holdings and Almac Group, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Pharmaceutical Rapid Sterility Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Pharmaceutical Rapid Sterility Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Pharmaceutical Rapid Sterility Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pharmaceutical Rapid Sterility Testing market.
Pharmaceutical Rapid Sterility Testing Segment by Company
Steris PLC
Charles River Laboratories International, Inc.
Thermo Fisher Scientific, Inc.
SGS S.A.
Sartorius AG
Sotera Health Company
Pacific Biolabs, Inc.
Laboratory Corporation of America Holdings
Almac Group
Pace Analytical Services, LLC
Pharmaceutical Rapid Sterility Testing Segment by Type
Bioburden Testing
Sterility Testing
Bacterial Endotoxin Testing
Pharmaceutical Rapid Sterility Testing Segment by Application
Pharmaceuticals
Medical Devices
Biopharmaceuticals
Pharmaceutical Rapid Sterility Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Pharmaceutical Rapid Sterility Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Pharmaceutical Rapid Sterility Testing key companies, revenue, market share, and recent developments.
3. To split the Pharmaceutical Rapid Sterility Testing breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Pharmaceutical Rapid Sterility Testing market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Pharmaceutical Rapid Sterility Testing significant trends, drivers, influence factors in global and regions.
6. To analyze Pharmaceutical Rapid Sterility Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmaceutical Rapid Sterility Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharmaceutical Rapid Sterility Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmaceutical Rapid Sterility Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pharmaceutical Rapid Sterility Testing industry.
Chapter 3: Detailed analysis of Pharmaceutical Rapid Sterility Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Pharmaceutical Rapid Sterility Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Pharmaceutical Rapid Sterility Testing in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Bioburden Testing
- Sterility Testing
- Bacterial Endotoxin Testing
Applications
- Pharmaceuticals
- Medical Devices
- Biopharmaceuticals
Companies covered
- Steris PLC
- Charles River Laboratories International, Inc.
- Thermo Fisher Scientific, Inc.
- SGS S.A.
- Sartorius AG
- Sotera Health Company
- Pacific Biolabs, Inc.
- Laboratory Corporation of America Holdings
- Almac Group
- Pace Analytical Services, LLC
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Pharmaceutical Rapid Sterility Testing Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Pharmaceutical Rapid Sterility Testing Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Pharmaceutical Rapid Sterility Testing Market Dynamics
- 2.1 Pharmaceutical Rapid Sterility Testing Industry Trends
- 2.2 Pharmaceutical Rapid Sterility Testing Industry Drivers
- 2.3 Pharmaceutical Rapid Sterility Testing Industry Opportunities and Challenges
- 2.4 Pharmaceutical Rapid Sterility Testing Industry Restraints
3 Pharmaceutical Rapid Sterility Testing Market by Company
- 3.1 Global Pharmaceutical Rapid Sterility Testing Company Revenue Ranking in 2025
- 3.2 Global Pharmaceutical Rapid Sterility Testing Revenue by Company (2021-2026)
- 3.3 Global Pharmaceutical Rapid Sterility Testing Company Ranking (2024-2026)
- 3.4 Global Pharmaceutical Rapid Sterility Testing Company Manufacturing Base and Headquarters
- 3.5 Global Pharmaceutical Rapid Sterility Testing Company Product Type and Application
- 3.6 Global Pharmaceutical Rapid Sterility Testing Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Pharmaceutical Rapid Sterility Testing Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Pharmaceutical Rapid Sterility Testing Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Pharmaceutical Rapid Sterility Testing Market by Type
- 4.1 Pharmaceutical Rapid Sterility Testing Type Introduction
- 4.1.1 Bioburden Testing
- 4.1.2 Sterility Testing
- 4.1.3 Bacterial Endotoxin Testing
- 4.2 Global Pharmaceutical Rapid Sterility Testing Sales Value by Type
- 4.2.1 Global Pharmaceutical Rapid Sterility Testing Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Pharmaceutical Rapid Sterility Testing Sales Value by Type (2021-2032)
- 4.2.3 Global Pharmaceutical Rapid Sterility Testing Sales Value Share by Type (2021-2032)
5 Pharmaceutical Rapid Sterility Testing Market by Application
- 5.1 Pharmaceutical Rapid Sterility Testing Application Introduction
- 5.1.1 Pharmaceuticals
- 5.1.2 Medical Devices
- 5.1.3 Biopharmaceuticals
- 5.2 Global Pharmaceutical Rapid Sterility Testing Sales Value by Application
- 5.2.1 Global Pharmaceutical Rapid Sterility Testing Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Pharmaceutical Rapid Sterility Testing Sales Value by Application (2021-2032)
- 5.2.3 Global Pharmaceutical Rapid Sterility Testing Sales Value Share by Application (2021-2032)
6 Pharmaceutical Rapid Sterility Testing Regional Value Analysis
- 6.1 Global Pharmaceutical Rapid Sterility Testing Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Pharmaceutical Rapid Sterility Testing Sales Value by Region (2021-2032)
- 6.2.1 Global Pharmaceutical Rapid Sterility Testing Sales Value by Region: 2021-2026
- 6.2.2 Global Pharmaceutical Rapid Sterility Testing Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Pharmaceutical Rapid Sterility Testing Sales Value (2021-2032)
- 6.3.2 North America Pharmaceutical Rapid Sterility Testing Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Pharmaceutical Rapid Sterility Testing Sales Value (2021-2032)
- 6.4.2 Europe Pharmaceutical Rapid Sterility Testing Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Pharmaceutical Rapid Sterility Testing Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Pharmaceutical Rapid Sterility Testing Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Pharmaceutical Rapid Sterility Testing Sales Value (2021-2032)
- 6.6.2 South America Pharmaceutical Rapid Sterility Testing Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Pharmaceutical Rapid Sterility Testing Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Pharmaceutical Rapid Sterility Testing Sales Value Share by Country, 2025 VS 2032
7 Pharmaceutical Rapid Sterility Testing Country-level Value Analysis
- 7.1 Global Pharmaceutical Rapid Sterility Testing Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Pharmaceutical Rapid Sterility Testing Sales Value by Country (2021-2032)
- 7.2.1 Global Pharmaceutical Rapid Sterility Testing Sales Value by Country (2021-2026)
- 7.2.2 Global Pharmaceutical Rapid Sterility Testing Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.7.2 France Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.14.2 China Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.17.2 India Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Pharmaceutical Rapid Sterility Testing Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Pharmaceutical Rapid Sterility Testing Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Pharmaceutical Rapid Sterility Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Steris PLC
- 8.1.1 Steris PLC Company Information
- 8.1.2 Steris PLC Business Overview
- 8.1.3 Steris PLC Pharmaceutical Rapid Sterility Testing Revenue and Gross Margin (2021-2026)
- 8.1.4 Steris PLC Pharmaceutical Rapid Sterility Testing Product Portfolio
- 8.1.5 Steris PLC Recent Developments
- 8.2 Charles River Laboratories International, Inc.
- 8.2.1 Charles River Laboratories International, Inc. Company Information
- 8.2.2 Charles River Laboratories International, Inc. Business Overview
- 8.2.3 Charles River Laboratories International, Inc. Pharmaceutical Rapid Sterility Testing Revenue and Gross Margin (2021-2026)
- 8.2.4 Charles River Laboratories International, Inc. Pharmaceutical Rapid Sterility Testing Product Portfolio
- 8.2.5 Charles River Laboratories International, Inc. Recent Developments
- 8.3 Thermo Fisher Scientific, Inc.
- 8.3.1 Thermo Fisher Scientific, Inc. Company Information
- 8.3.2 Thermo Fisher Scientific, Inc. Business Overview
- 8.3.3 Thermo Fisher Scientific, Inc. Pharmaceutical Rapid Sterility Testing Revenue and Gross Margin (2021-2026)
- 8.3.4 Thermo Fisher Scientific, Inc. Pharmaceutical Rapid Sterility Testing Product Portfolio
- 8.3.5 Thermo Fisher Scientific, Inc. Recent Developments
- 8.4 SGS S.A.
- 8.4.1 SGS S.A. Company Information
- 8.4.2 SGS S.A. Business Overview
- 8.4.3 SGS S.A. Pharmaceutical Rapid Sterility Testing Revenue and Gross Margin (2021-2026)
- 8.4.4 SGS S.A. Pharmaceutical Rapid Sterility Testing Product Portfolio
- 8.4.5 SGS S.A. Recent Developments
- 8.5 Sartorius AG
- 8.5.1 Sartorius AG Company Information
- 8.5.2 Sartorius AG Business Overview
- 8.5.3 Sartorius AG Pharmaceutical Rapid Sterility Testing Revenue and Gross Margin (2021-2026)
- 8.5.4 Sartorius AG Pharmaceutical Rapid Sterility Testing Product Portfolio
- 8.5.5 Sartorius AG Recent Developments
- 8.6 Sotera Health Company
- 8.6.1 Sotera Health Company Company Information
- 8.6.2 Sotera Health Company Business Overview
- 8.6.3 Sotera Health Company Pharmaceutical Rapid Sterility Testing Revenue and Gross Margin (2021-2026)
- 8.6.4 Sotera Health Company Pharmaceutical Rapid Sterility Testing Product Portfolio
- 8.6.5 Sotera Health Company Recent Developments
- 8.7 Pacific Biolabs, Inc.
- 8.7.1 Pacific Biolabs, Inc. Company Information
- 8.7.2 Pacific Biolabs, Inc. Business Overview
- 8.7.3 Pacific Biolabs, Inc. Pharmaceutical Rapid Sterility Testing Revenue and Gross Margin (2021-2026)
- 8.7.4 Pacific Biolabs, Inc. Pharmaceutical Rapid Sterility Testing Product Portfolio
- 8.7.5 Pacific Biolabs, Inc. Recent Developments
- 8.8 Laboratory Corporation of America Holdings
- 8.8.1 Laboratory Corporation of America Holdings Company Information
- 8.8.2 Laboratory Corporation of America Holdings Business Overview
- 8.8.3 Laboratory Corporation of America Holdings Pharmaceutical Rapid Sterility Testing Revenue and Gross Margin (2021-2026)
- 8.8.4 Laboratory Corporation of America Holdings Pharmaceutical Rapid Sterility Testing Product Portfolio
- 8.8.5 Laboratory Corporation of America Holdings Recent Developments
- 8.9 Almac Group
- 8.9.1 Almac Group Company Information
- 8.9.2 Almac Group Business Overview
- 8.9.3 Almac Group Pharmaceutical Rapid Sterility Testing Revenue and Gross Margin (2021-2026)
- 8.9.4 Almac Group Pharmaceutical Rapid Sterility Testing Product Portfolio
- 8.9.5 Almac Group Recent Developments
- 8.10 Pace Analytical Services, LLC
- 8.10.1 Pace Analytical Services, LLC Company Information
- 8.10.2 Pace Analytical Services, LLC Business Overview
- 8.10.3 Pace Analytical Services, LLC Pharmaceutical Rapid Sterility Testing Revenue and Gross Margin (2021-2026)
- 8.10.4 Pace Analytical Services, LLC Pharmaceutical Rapid Sterility Testing Product Portfolio
- 8.10.5 Pace Analytical Services, LLC Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst